ERIS For Loss-Making Small SMEs, Does The 27% Cash Credit Stack Up?
ERIS for Loss-Making SMEs: Does the 27% Cash Credit Stack Up?
The Enhanced R&D Intensive Support scheme provides a payable tax credit of up to 27% of qualifying R&D expenditure for loss-making SMEs whose R&D spending represents at least 30% of their total expenditure. The "up to" qualification matters considerably. For smaller companies with modest payrolls, the PAYE and NIC cap restricts the actual amount receivable to well below that headline figure, and understanding where the cap bites is the most important analytical step before relying on ERIS to fund operations.
What ERIS Is and How It Differs from the Merged RDEC
ERIS applies to accounting periods beginning on or after 1 April 2024 and sits alongside the merged RDEC scheme rather than replacing it. Most companies, including most profitable SMEs, claim under the merged scheme at a 20% above-the-line credit rate. The net benefit after corporation tax at 25% is approximately 15p per pound of qualifying spend.
ERIS preserves the mechanics of the old SME loss-maker surrender route for the subset of companies that meet its conditions. The mechanical distinction is meaningful: under the merged RDEC, the credit is above-the-line and taxable, so profitability and corporation tax rate directly affect the net benefit. Under ERIS, the benefit is calculated as 14.5% of the surrenderable loss, with an enhanced deduction of 86% of qualifying R&D costs, resulting in a cash benefit of up to 27p per £1 spent on R&D. That payable credit is not contingent on future profitability. It is receivable regardless of whether the company ever pays corporation tax.
For a genuinely R&D-intensive loss-making SME, ERIS therefore delivers cash now rather than a tax reduction later. That distinction has real planning significance for companies burning through investor funding and waiting for commercial traction.
Where Does the 27% Figure Come From?
The arithmetic deserves a direct explanation because it is frequently stated without derivation, which leads to confusion about what drives it and whether it changes.
ERIS applies an 86% additional deduction on top of the normal 100% deduction for qualifying R&D expenditure. Total deduction: 186% of qualifying spend. For a company spending £100,000 on qualifying R&D, the deduction against trading profits is £186,000 rather than £100,000. Since the company is already loss-making, this enhanced deduction deepens the trading loss.
The company can then surrender the enhanced trading loss for a payable credit at 14.5%. The credit is computed on the surrenderable loss, which in most cases approximates to the total qualifying R&D expenditure grossed up by the 186% enhancement factor. Working through the numbers: 14.5% multiplied by 186% equals approximately 26.97%, conventionally described as 27%.
So the 27% is not a statutory rate in itself. It is the product of two figures: the 14.5% credit rate on the surrenderable loss and the 186% total deduction factor. If either component changed, the 27% headline would change with it. Neither is currently scheduled to change for 2026/27.
What this Widget is About: The ERIS Explainer Widget is designed to help loss-making SMEs in the UK determine whether they truly qualify for the headline 27% cash credit on their research and development expenditure. While the scheme offers generous support, the actual payout is often severely restricted by the PAYE and National Insurance Contributions (NIC) cap, which catches many early-stage businesses by surprise. This interactive tool instantly calculates your R&D intensity ratio to confirm if you meet the strict 30% threshold required to access the scheme. To use the calculator, simply input your total business expenditure, your qualifying R&D costs, and your annual PAYE and NIC liabilities into the designated fields. Within seconds, the widget will bypass the confusing arithmetic to reveal your actual projected cash credit, ensuring you can make fully informed financial forecasts for your business.
Who Qualifies for ERIS in 2026/27?
The SME Definition
To qualify as an SME for R&D purposes, the company must employ fewer than 500 employees and have either annual turnover of less than €100 million or balance sheet assets of less than €86 million. These thresholds are applied at the group level, aggregating the figures of connected and partner enterprises. A company that sits within a group controlled by a large corporate parent would not be an SME regardless of its own size.
The Loss-Making Condition
The company must be loss-making for the accounting period in question, assessed on tax-adjusted trading profits before the R&D enhancement itself is applied. A company that would be profitable without the R&D deduction but moves into loss once the deduction is applied does not satisfy the condition. The loss must exist independently of the R&D claim.
This creates an important distinction from the merged RDEC, where profitability is irrelevant to the structure of the relief. A company that expects to turn profitable in the next year should model both the ERIS and merged RDEC positions carefully, since the optimum route depends on the timing of future profitability and the projected credit compared with a deferred CT saving.
The 30% Intensity Test
For accounting periods beginning on or after 1 April 2024, the R&D intensity threshold is 30%. The test requires that qualifying R&D expenditure represents at least 30% of the company's total relevant expenditure for the period.
Total relevant expenditure is broadly the company's operating costs for the period, excluding capital disposals, investment returns, and corporation tax payments. It does not equate to turnover. A software company spending £400,000 on staff and operating costs in total, of which £130,000 qualifies as R&D, achieves an intensity ratio of 32.5%. That clears the 30% threshold.
Where connected companies are involved, their qualifying R&D expenditure is aggregated with the claiming company's own R&D for the numerator. This can assist group companies in reaching the threshold where R&D activity is spread across entities in the same ownership structure.
The Grace Period
A company that met the 30% intensity condition in the previous accounting period can still claim ERIS in the current period even if its R&D intensity drops below 30%. This one-year grace period prevents a company losing ERIS entitlement because of a single year in which R&D spending temporarily fell as a proportion of total costs, perhaps because a large commercial contract inflated revenue or an unusually high non-R&D cost arose in the period. The grace year is not automatic: the company must have genuinely met the intensity condition in the preceding period, and its loss-making status must continue to be satisfied. A company using the grace period should document its prior-year intensity calculation clearly in its records.
ERIS for UK SMEs: 27% Cash Credit Analysis
Scheme Parameter | Enhanced R&D Intensive Support (ERIS) Detail | User Impact or Requirement |
R&D Intensity Gateway | Loss-making SMEs must spend at least 30% of total expenditure on qualifying R&D (reduced from 40% for periods starting on or after 1 April 2024). This calculation must aggregate the expenditure of all globally connected companies. | A one-year 'year of grace' applies if a company met the threshold in the previous period. Failure to meet the 30% intensity ratio relegates the claim to the standard Merged Scheme (16.2% net relief). |
Credit Yield (26.97% Cash Credit) | Provides an 86% enhanced deduction on top of the 100% core spend. The resulting loss is surrendered for a 14.5% payable credit (1.86 \times 14.5\% = 26.97\%). | The headline 26.97% is a net cash benefit for every £100 spent. However, if pre-R&D losses are small, the yield may drop; if the surrenderable loss is less than 60% of the enhanced expenditure, the Merged Scheme may be more beneficial. |
Practical Limitations (PAYE Cap & Caps) | The payable credit is capped at £20,000 plus 300% of the company's relevant PAYE and NIC liabilities. Most overseas subcontractor and Externally Provided Worker (EPW) costs are also excluded from 1 April 2024. | Startups with low UK headcount or those using offshore development teams may see their cash claim significantly restricted regardless of R&D intensity. Unlike the Merged Scheme, excess credit above the cap cannot be carried forward. |
Compliance & Loss-Surrender | Mandatory submission of a digital Additional Information Form (AIF) before the CT600. The company must be 'loss-making' for tax purposes before the R&D enhancement is applied. | Failure to submit the AIF leads to immediate rejection. Companies must ensure their loss-making status is GAAP-compliant; profit-making SMEs or those only made loss-making by the deduction do not qualify for the 14.5% rate. |
The PAYE and NIC Cap: Where the 27% Often Falls Short
The most significant constraint on ERIS for smaller companies is the cap on the payable credit by reference to PAYE and NIC liabilities. The maximum payable credit a company can receive under ERIS is limited to three times its total PAYE and NIC payments for the relevant period, plus £20,000.
The formula: maximum payable credit equals (total PAYE and NIC for the period × 300%) plus £20,000.
For a company with annual PAYE and NIC of £50,000, the cap allows a payable credit of up to £170,000. For a company with PAYE and NIC of £15,000, the maximum credit is £65,000. For a company with no employees, or only the director paid through dividends rather than PAYE, the cap restricts the payable credit to a maximum of £20,000 regardless of R&D spend.
A worked example illustrates how sharply the cap can bite. Consider a two-person founding team operating through a limited company in its second year. They pay themselves £12,570 each through PAYE, creating minimal NIC liability. Their R&D spend is £300,000 in the period, consisting primarily of consultancy and subcontract costs. Qualified under the intensity and loss-making conditions, the theoretical ERIS credit would be approximately £81,000 (27% of £300,000). But their combined PAYE and NIC is roughly £3,000. The cap allows: (£3,000 × 3) + £20,000 = £29,000.
The company receives £29,000, not £81,000. The remaining £52,000 of credit is not payable. It cannot be carried back or forward in payable form. That is a significant gap between the headline and the reality.
The cap was introduced in 2021 to address the use of R&D payable credits by companies without genuine employment activity. Its continued presence in ERIS has the consequence that early-stage companies dependent on founder effort and external subcontractors, where payroll is minimal, are systematically disadvantaged relative to the headline rate.
The practical implication is that the 27% figure should never be used in cashflow forecasting without first confirming the company's actual PAYE and NIC position and computing the cap. This step is consistently overlooked in early engagements where an adviser or advisor quotes the headline rate without doing the arithmetic.
What Counts as Qualifying R&D Expenditure Under ERIS
ERIS inherits the qualifying cost categories from the old SME scheme rather than from the merged RDEC framework, though in practice the categories align closely. Qualifying costs include:
Staff costs: salaries, wages, employer NIC, pension contributions, and other employment costs for employees directly engaged in R&D activity, apportioned for employees who also spend time on non-R&D work.
Subcontractor costs: 65% of payments to unconnected subcontractors are qualifying costs under ERIS. For connected subcontractors, the actual expenditure on qualifying R&D by the subcontractor is the relevant amount, subject to the total capped at 65% of the contracted amount.
Consumables: materials and utilities used directly and consumed in R&D activities.
Software: licence costs for software used directly in R&D.
Cloud computing: costs for cloud computing resources used for R&D purposes have been qualifying costs since April 2023 under the previous SME scheme, and continue under ERIS.
Capital expenditure is not qualifying under ERIS. The cost of equipment, laboratory fit-outs, or intellectual property purchased from third parties is not included. This is a point of confusion for companies whose R&D programme requires significant capital investment: the ongoing operational costs of running qualifying activities may qualify, but the initial capital cost does not.
What this Widget is About: This interactive widget helps loss-making UK SMEs understand whether the ERIS headline cash credit of up to 27% is actually achievable in practice. It explains the key conditions, including SME status, the 30% R&D intensity test, the loss-making requirement, and the PAYE/NIC cap. Use the calculator by entering your qualifying R&D costs, total relevant expenditure, trading loss, payroll taxes and accounting period length. The widget then estimates the theoretical ERIS credit, the capped cash amount, and a comparison with the merged RDEC position. It is designed as a practical first-look guide, but companies should take tailored advice before submitting an R&D tax relief claim.
ERIS vs Merged RDEC: Making the Right Choice
For a loss-making SME meeting the 30% intensity test in 2026/27, ERIS should produce a better outcome than the merged RDEC, subject to the PAYE cap not being the binding constraint.
Under the merged RDEC, the 20% credit is above the line and then taxed as income. For a loss-making company with no tax liability, the net credit is 20% of qualifying expenditure with no reduction for tax. That compares with ERIS at up to 27%. ERIS is superior in both cases where the PAYE cap allows the full credit through.
Where the PAYE cap restricts ERIS to below what merged RDEC would generate, the analysis reverses. A company whose PAYE/NIC position limits its ERIS payable credit to, say, £25,000 on £200,000 of qualifying spend, would receive £40,000 under the merged RDEC. In that scenario, the merged RDEC route is the correct choice.
From the 2026/27 position, HMRC has not signalled any planned change to the ERIS rate or the intensity threshold for the near term, though the Autumn Budget 2025 included a general direction that R&D reliefs will continue to be reviewed for value and integrity. No specific change to ERIS was announced.
Not Sure How ERIS Works for SMEs?
The general rule is one thing. What it means for you is another. Tell us your circumstances and one of our UK tax specialists will give you a straight answer on your own position. Free, no obligation.
The Northern Ireland Position
Companies with a registered office in Northern Ireland are subject to different rules under the Finance Act 2025 provisions, which take effect for claims made on or after 30 October 2024. The Northern Ireland position reflects subsidy control obligations under the UK-EU Trade and Cooperation Agreement. The ERIS payable credit may not be available in its full form for Northern Ireland-registered companies in certain circumstances. Companies with a Northern Ireland registered office should take specific advice on whether the standard ERIS credit calculation applies before making a claim.
Practical Steps for an ERIS Claim in 2026/27
The first step is confirming whether the company is genuinely loss-making for the period on a tax-adjusted basis, before the R&D deduction is applied. If it is profitable before the R&D deduction and only enters loss once the enhanced deduction is applied, it does not satisfy the condition.
The second step is computing the intensity ratio. This requires identifying total relevant expenditure for the period correctly, particularly where the company has unusual cost items or connected party arrangements that affect the denominator. Errors in the denominator calculation are a common cause of incorrect intensity assessments.
The third step is computing the PAYE and NIC cap based on actual payroll data for the period. If the cap restricts the available credit below what merged RDEC would generate, the claim route should be reconsidered.
The fourth step is confirming pre-notification. A first-time ERIS claimant that has not submitted a valid prior R&D claim must have submitted the claim notification form to HMRC within six months of the end of the accounting period before the ERIS claim can be made. Submitting an ERIS claim without that prior notification renders the claim invalid with no right of appeal.
The fifth step is completing the Additional Information Form with the level of technical and financial detail HMRC expects, including project descriptions, qualifying cost breakdowns by category, and the basis for the intensity calculation.
Key Takeaways
ERIS is available for accounting periods beginning on or after 1 April 2024 to loss-making SMEs where qualifying R&D expenditure is at least 30% of total expenditure, providing a payable cash credit of up to 27% of qualifying R&D spend.
The 27% derives from a 14.5% credit rate applied to a surrenderable loss enhanced by an 86% additional deduction, producing an effective 26.97% of the original qualifying expenditure.
The PAYE and NIC cap limits the payable credit to three times the company's total PAYE and NIC liabilities for the period, plus £20,000. For companies with minimal payroll, the cap may restrict the effective benefit to well below 27%.
The grace period allows a company to claim ERIS in a period where intensity falls below 30%, provided it met the 30% condition in the immediately preceding period.
A first-time ERIS claimant must have submitted a claim notification form within six months of the accounting period end. Without it, the claim is invalid.
The 27% figure is only achievable where the PAYE cap is not the binding constraint. Modelling the actual payable credit against the merged RDEC alternative is an essential step before committing to ERIS as the claim route.
FAQs
Q1: What happens if my SME's R&D intensity dips just below 30% in one year due to a big non-R&D contract win?
Well, it's worth noting that HMRC provides a one-year grace period for companies that previously met the 30% threshold. In my experience with clients in Manchester running software firms, this has saved several from losing out when they landed a large implementation project that boosted overall expenditure. You'd still qualify for ERIS that year if you met it the prior period, but plan ahead by forecasting your spending carefully, perhaps accelerating some qualifying R&D to maintain the ratio where possible. Always double-check your total expenditure calculation, as it includes everything from salaries to office rent.
Q2: Can a self-employed director of a loss-making SME claim ERIS personally, or does it only apply at company level?
In practice, ERIS is strictly a corporation tax relief for the company itself, not something individuals claim on self-assessment. I've advised several tech founders in Edinburgh who tried mixing personal and company claims, it's a common mix-up. The relief enhances the company's trading loss and provides the cash credit to the business. If you're taking dividends or salary, ensure your personal tax position doesn't inadvertently create a profit at company level that disqualifies the loss-making status. A quick review of your extraction strategy can make all the difference.
Q3: How does ERIS interact with grant funding or other state aid for my small manufacturing business?
It's a frequent point of confusion. Unlike older rules, the merged scheme and ERIS are more flexible with subsidised expenditure, but you mustn't double-dip. Consider a hypothetical client in Birmingham running a precision engineering firm that received Innovate UK grant money: we allocated qualifying R&D costs carefully to maximise the ERIS credit without breaching state aid caps. The payable credit remains valuable, but track everything meticulously, overclaiming here has led to enquiries in my experience.
Q4: What are the pitfalls for high-growth loss-making SMEs approaching the employee or turnover limits for SME status?
Many owners don't realise how quickly they can breach the thresholds when including connected companies. In one case with a London biotech startup, rapid hiring pushed them over just as they hit a strong R&D year, forcing a switch out of ERIS. Review group structures early and consider the €100m turnover or €86m balance sheet tests on a consolidated basis. It's better to plan an orderly transition to the main merged scheme than face a sudden drop in relief.
Q5: Does the 27% cash credit stack up better than the merged scheme if my company has some marginal profits in certain periods?
The effective benefit depends on your exact loss position. I've seen situations where companies with small profits or marginal losses actually fare better under the main merged scheme due to how the credit is calculated and taxed. For a freelancer-turned-SME owner in Leeds developing AI tools, running both scenarios side-by-side showed ERIS winning only when losses were substantial relative to R&D spend. Model it properly, there's a tipping point around where losses are less than about 25-30% of R&D costs where the other route might deliver more cash.
Q6: How do regional differences, like operating in Scotland or Northern Ireland, affect an ERIS claim?
While the core rates are UK-wide, corporation tax interactions and certain devolved reliefs can influence the net outcome. A client with operations split between Glasgow and England found Scottish income tax nuances affected director remuneration, which in turn impacted the company's trading loss calculation for ERIS eligibility. Northern Ireland has specific provisions in some years too. It's rarely a deal-breaker but worth factoring into your overall tax planning, especially with different rates or incentives.
Q7: What should I do if HMRC queries my ERIS claim regarding the qualifying R&D projects?
Stay calm and respond promptly with clear, contemporaneous evidence. In my 15+ years, the strongest defences come from detailed project records showing technological uncertainty and advancement attempts, not just commercial success. One software house in Bristol I advised had a query resolved quickly by providing timesheets and technical reports prepared at the time, rather than retrospective notes. Engage a specialist early if needed, but don't overcomplicate, focus on facts that match HMRC's guidelines.
Q8: Can ERIS be claimed if my loss-making SME has international subcontractors or remote workers?
Yes, but the rules on qualifying expenditure are strict. Costs for subcontractors must relate to UK R&D activity in many cases, though there is some scope. I've worked with a games development studio in Cardiff using overseas talent where we successfully claimed for the UK-managed elements. Keep robust contracts and apportionment records. Remote UK-based workers are generally fine as long as the company directs the R&D. This area trips up many expanding businesses.
Q9: What are the PAYE/NIC caps on the ERIS cash credit, and how do they apply in practice?
The credit is capped based on your PAYE and NIC liabilities, designed to prevent abuse. For a genuine early-stage biotech firm I advised that had minimal staff costs initially, this meant staggering claims or carrying forward elements. It's less restrictive than before but still relevant for very small teams or those relying heavily on contractors. Calculate it alongside your claim to avoid nasty surprises when the payment arrives, or doesn't.
Q10: How might claiming ERIS affect future funding rounds or business valuations for loss-making SMEs?
Investors often view the cash credit positively as non-dilutive funding, but ensure your accounts clearly show it as a below-the-line item. In several cases with venture-backed clients, we've structured claims to strengthen the balance sheet without creating taxable income. Be transparent in due diligence, surprises here can delay deals. It can genuinely improve cash runway, making your business more attractive if positioned as support for ongoing innovation.
About the Author:
Adil Akhtar, ACMA, CGMA, FCMA (membership ID is 990250923) serves as CEO and Chief Accountant at Pro Tax Accountant, bringing over 18 years of expertise in tackling intricate tax issues. As a respected tax blog writer, Adil has spent more than eighteen years delivering clear, practical advice to UK taxpayers. He also leads Advantax Accountants (registered with Companies House), combining technical expertise with a passion for simplifying complex financial concepts, establishing himself as a trusted voice in tax education.
Email: adilacma@icloud.com
Disclaimer:
The content provided in our articles is for general informational purposes only and should not be considered professional advice. Pro Tax Accountant strives to ensure the accuracy and timeliness of the information but makes no guarantees, express or implied, regarding its completeness, reliability, suitability, or availability. Any reliance on this information is at your own risk. Note that some data presented in charts or graphs may not be 100% accurate.
.png)